The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

AbCellera, a Canada-based antibody therapy developer based on University of British Columbia research and also backed by University of Minnesota, closed its initial public offering at approximately $556m yesterday. Founded in 2012, AbCellera analyses the human immune system to locate and identify antibodies that could be made into drug treatments. It is collaborating with pharmaceutical…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.